Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITI Phase 3 study of subcutaneous guselkumab induction in moderately to severely active Crohn's disease
2023-504737-41-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Guselkumab with Placebo (2 arms). Primary endpoints: Clinical remission at Week 12 and Endoscopic response at Week 12. Planned start Jun 2022; status: authorised.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-504737-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504737-41-00.